Effectiveness of ustekinumab in patients with refractory Crohn's disease: a multicentre real-life study in Italy.

ABSTRACT:

Background

The effectiveness of ustekinumab in patients with refractory Crohn's disease (CD) has been investigated in several real-world studies. However, very few data concerning the real-life experience in Italy have been reported. Therefore, this study assessed the effectiveness of ustekinumab in a large cohort of Italian patients with refractory CD.

Methods

All patients who had started on ustekinumab after failure of or intolerance to antitumour necrosis factor-α (TNF-α) treatment at five tertiary centres between November 2018 and February 2020 were retrospectively enrolled. The coprimary outcome was corticosteroid-free clinical remission, defined as a Harvey-Bradshaw Index (HBI) score of ⩽4, at weeks 26 and 52. The secondary outcomes were changes in the HBI and C-reacti

SUBMITTER: Scribano ML 

PROVIDER: S-EPMC8848093 | biostudies-literature | 2022

REPOSITORIES: biostudies-literature